Extracellular vesicle-mediated gene therapy targets BRAFV600E-mutant colorectal cancer by inhibiting the MEK1/2-ERK1/2 pathway
The therapeutic EVs we constructed are effective and specific for the BRAF<sup>V600E</sup>-mutant CRC. This study provides a novel strategy for the treatment of CRC patients with BRAF<sup>V600E</sup> mutation.
Authors
- Minjun Yao (ORCID: https://orcid.org/0000-0002-0287-1745)
- Chenyi Ye
- Wei Zhan (ORCID: https://orcid.org/0000-0002-7167-6353)
- Liming Zheng (ORCID: https://orcid.org/0000-0001-6380-3191)
- Kaile Wu (ORCID: https://orcid.org/0000-0002-6578-5000)
- Jianbin Xu (ORCID: https://orcid.org/0000-0003-0509-9508)
- Jisheng Ran
- Zhigang Guo (ORCID: https://orcid.org/0000-0001-7771-1829)
- Yubin Zhao
- Liang Chen (ORCID: https://orcid.org/0000-0002-3605-8883)
- Xin Liu (ORCID: https://orcid.org/0000-0002-0961-0708)
- Di Wang (ORCID: https://orcid.org/0000-0002-1995-8118)
- Liwei Wang (ORCID: https://orcid.org/0000-0002-5346-5886)
- Wei Zhou (ORCID: https://orcid.org/0000-0003-0322-095X)
- Kaicheng Xu (ORCID: https://orcid.org/0000-0002-3615-0807)
- Donghua Huang
Institutions
- Sir Run Run Shaw Hospital (CN)
- Zhejiang Lab (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Journal of Nanobiotechnology
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1186/s12951-025-03205-4
- Citations
- 5
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 4.03
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province